Lupin launches Minocycline Hydrochloride extended release tablets in US
The company has launched Minocycline Hydrochloride extended-release tablets USP in the strength of 55 mg, after receiving approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said.
Mumbai: Drug major, Lupin has recently launched Minocycline Hydrochloride extended-release tablets in the US market. Minocycline Hydrochloride is used to treat inflammatory lesions of acne. However, the tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
The company has launched Minocycline Hydrochloride extended-release tablets USP in the strength of 55 mg, after receiving approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said.
Also Read: Lupin gets USFDA nod to Methylprednisolone tablets to treat inflammation
As per IQVIA MAT December 2018 data, the product had annual sales of around $76.8 million in the US, Lupin said.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd